Search Results
Search for other papers by P Pallante in
Google Scholar
PubMed
Search for other papers by R Visone in
Google Scholar
PubMed
Search for other papers by M Ferracin in
Google Scholar
PubMed
Search for other papers by A Ferraro in
Google Scholar
PubMed
Search for other papers by M T Berlingieri in
Google Scholar
PubMed
Search for other papers by G Troncone in
Google Scholar
PubMed
Search for other papers by G Chiappetta in
Google Scholar
PubMed
Search for other papers by C G Liu in
Google Scholar
PubMed
Search for other papers by M Santoro in
Google Scholar
PubMed
Search for other papers by M Negrini in
Google Scholar
PubMed
Search for other papers by C M Croce in
Google Scholar
PubMed
Search for other papers by A Fusco in
Google Scholar
PubMed
different degrees of malignancy from benign adenomas, which are not invasive and very well differentiated, to the undifferentiated anaplastic thyroid carcinomas, which are very aggressive and always fatal. Papillary and follicular carcinomas, the most common
Search for other papers by Alfred King-yin Lam in
Google Scholar
PubMed
Search for other papers by Nassim Saremi in
Google Scholar
PubMed
Introduction Cribriform-morular variant of papillary thyroid carcinoma (CMV-PTC) is an uncommon variant of papillary thyroid carcinoma. It is a variant of papillary thyroid carcinoma recognized in the current World Health Organization (WHO
Northern Clinical School, Sydney Medical School, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia
Search for other papers by Henry Crayton in
Google Scholar
PubMed
Search for other papers by Katherine Wu in
Google Scholar
PubMed
Search for other papers by David Leong in
Google Scholar
PubMed
Search for other papers by Nazim Bhimani in
Google Scholar
PubMed
Department of Endocrinology, Royal North Shore Hospital, Northern Sydney Local Health District, St Leonards, New South Wales, Australia
Search for other papers by Matti Gild in
Google Scholar
PubMed
Northern Clinical School, Sydney Medical School, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia
The Kinghorn Cancer Centre, Garvan Institute of Medical Research, St. Vincent’s Clinical School, Faculty of Medicine, University of New South Wales, Darlinghurst, New South Wales, Australia
Search for other papers by Anthony Glover in
Google Scholar
PubMed
Introduction Papillary thyroid carcinoma (PTC) is the most common type of endocrine cancer, comprising 80% of all thyroid cancers ( Hundahl et al. 2000 ). The diffuse sclerosing variant (DSV) of PTC is a rare variant, comprising 0.7–5.3% of
Search for other papers by Kensey Bergdorf in
Google Scholar
PubMed
Search for other papers by Donna C Ferguson in
Google Scholar
PubMed
Search for other papers by Mitra Mehrad in
Google Scholar
PubMed
Search for other papers by Kim Ely in
Google Scholar
PubMed
Search for other papers by Thomas Stricker in
Google Scholar
PubMed
Search for other papers by Vivian L Weiss in
Google Scholar
PubMed
analysis. In this Institutional Review Board approved study, files from 2008 to 2017 containing diagnoses of classical papillary thyroid carcinoma (PTC, N = 20), follicular variant of PTC (FVTPC, N = 12) and non-invasive follicular thyroid neoplasm with
Search for other papers by Luca Morandi in
Google Scholar
PubMed
Search for other papers by Alberto Righi in
Google Scholar
PubMed
Search for other papers by Francesca Maletta in
Google Scholar
PubMed
Search for other papers by Paola Rucci in
Google Scholar
PubMed
Search for other papers by Fabio Pagni in
Google Scholar
PubMed
Search for other papers by Marco Gallo in
Google Scholar
PubMed
Search for other papers by Sabrina Rossi in
Google Scholar
PubMed
Search for other papers by Leonardo Caporali in
Google Scholar
PubMed
Search for other papers by Anna Sapino in
Google Scholar
PubMed
Search for other papers by Ricardo V Lloyd in
Google Scholar
PubMed
Search for other papers by Sofia Asioli in
Google Scholar
PubMed
Introduction Thyroid cancer is the most common type of endocrine malignancy. The vast majority of thyroid tumors originate from thyroid follicular cells and encompasses well-differentiated papillary carcinoma and follicular carcinoma. Its
Search for other papers by Rodolfo Iuliano in
Google Scholar
PubMed
Dipartimento di Medicina Sperimentale e Clinica, Istituto di Endocrinologia ed Oncologia Sperimentale del CNR c/o Dipartimento di Biologia e Patologia Cellulare e Molecolare c/o, NOGEC (Naples Oncogenomic Center) – CEINGE, Division of Human Cancer Genetics, Sezione di Endocrinologia, Facoltà di Medicina e Chirurgia, Università degli Studi ‘Magna Græcia’ di Catanzaro, Campus ‘Salvatore Venuta’ Viale Europa, località Germaneto, 88100 Catanzaro, Italy
Search for other papers by Dario Palmieri in
Google Scholar
PubMed
Search for other papers by Huiling He in
Google Scholar
PubMed
Dipartimento di Medicina Sperimentale e Clinica, Istituto di Endocrinologia ed Oncologia Sperimentale del CNR c/o Dipartimento di Biologia e Patologia Cellulare e Molecolare c/o, NOGEC (Naples Oncogenomic Center) – CEINGE, Division of Human Cancer Genetics, Sezione di Endocrinologia, Facoltà di Medicina e Chirurgia, Università degli Studi ‘Magna Græcia’ di Catanzaro, Campus ‘Salvatore Venuta’ Viale Europa, località Germaneto, 88100 Catanzaro, Italy
Search for other papers by Angela Iervolino in
Google Scholar
PubMed
Dipartimento di Medicina Sperimentale e Clinica, Istituto di Endocrinologia ed Oncologia Sperimentale del CNR c/o Dipartimento di Biologia e Patologia Cellulare e Molecolare c/o, NOGEC (Naples Oncogenomic Center) – CEINGE, Division of Human Cancer Genetics, Sezione di Endocrinologia, Facoltà di Medicina e Chirurgia, Università degli Studi ‘Magna Græcia’ di Catanzaro, Campus ‘Salvatore Venuta’ Viale Europa, località Germaneto, 88100 Catanzaro, Italy
Search for other papers by Eleonora Borbone in
Google Scholar
PubMed
Dipartimento di Medicina Sperimentale e Clinica, Istituto di Endocrinologia ed Oncologia Sperimentale del CNR c/o Dipartimento di Biologia e Patologia Cellulare e Molecolare c/o, NOGEC (Naples Oncogenomic Center) – CEINGE, Division of Human Cancer Genetics, Sezione di Endocrinologia, Facoltà di Medicina e Chirurgia, Università degli Studi ‘Magna Græcia’ di Catanzaro, Campus ‘Salvatore Venuta’ Viale Europa, località Germaneto, 88100 Catanzaro, Italy
Search for other papers by Pierlorenzo Pallante in
Google Scholar
PubMed
Search for other papers by Alessandra Cianflone in
Google Scholar
PubMed
Search for other papers by Rebecca Nagy in
Google Scholar
PubMed
Search for other papers by Hansjuerg Alder in
Google Scholar
PubMed
Search for other papers by George A Calin in
Google Scholar
PubMed
Search for other papers by Francesco Trapasso in
Google Scholar
PubMed
Search for other papers by Carla Giordano in
Google Scholar
PubMed
Search for other papers by Carlo M Croce in
Google Scholar
PubMed
Search for other papers by Albert de la Chapelle in
Google Scholar
PubMed
Dipartimento di Medicina Sperimentale e Clinica, Istituto di Endocrinologia ed Oncologia Sperimentale del CNR c/o Dipartimento di Biologia e Patologia Cellulare e Molecolare c/o, NOGEC (Naples Oncogenomic Center) – CEINGE, Division of Human Cancer Genetics, Sezione di Endocrinologia, Facoltà di Medicina e Chirurgia, Università degli Studi ‘Magna Græcia’ di Catanzaro, Campus ‘Salvatore Venuta’ Viale Europa, località Germaneto, 88100 Catanzaro, Italy
Search for other papers by Alfredo Fusco in
Google Scholar
PubMed
Introduction Papillary thyroid carcinoma (PTC), a differentiated tumor arising from the follicular cells of thyroid, is the most frequent type of thyroid cancer. Although a major risk factor for PTC is the exposure to ionizing radiations ( Nagataki
Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden
Department of Breast, Endocrine Tumors and Sarcoma, Karolinska University Hospital, Stockholm, Sweden
Search for other papers by Adam Stenman in
Google Scholar
PubMed
Search for other papers by Samuel Backman in
Google Scholar
PubMed
Search for other papers by Klara Johansson in
Google Scholar
PubMed
Search for other papers by Johan O Paulsson in
Google Scholar
PubMed
Search for other papers by Peter Stålberg in
Google Scholar
PubMed
Department of Breast, Endocrine Tumors and Sarcoma, Karolinska University Hospital, Stockholm, Sweden
Search for other papers by Jan Zedenius in
Google Scholar
PubMed
Department of Pathology and Cytology, Karolinska University Hospital, Stockholm, Sweden
Search for other papers by C Christofer Juhlin in
Google Scholar
PubMed
-cell derived neoplasia denoted as pediatric papillary thyroid carcinoma (pPTC) or pediatric follicular thyroid carcinoma, while small subsets of cases are derived from the parafollicular C-cells; namely pediatric medullary thyroid carcinoma. As in adult
Search for other papers by Seog Yun Park in
Google Scholar
PubMed
Search for other papers by Yuh-S Jung in
Google Scholar
PubMed
Search for other papers by Chang Hwan Ryu in
Google Scholar
PubMed
Search for other papers by Chang Yoon Lee in
Google Scholar
PubMed
Search for other papers by You Jin Lee in
Google Scholar
PubMed
Search for other papers by Eun Kyung Lee in
Google Scholar
PubMed
Search for other papers by Seok-Ki Kim in
Google Scholar
PubMed
Search for other papers by Tae Sung Kim in
Google Scholar
PubMed
Search for other papers by Tae Hyun Kim in
Google Scholar
PubMed
Search for other papers by Jeyun Jang in
Google Scholar
PubMed
Search for other papers by Daeyoon Park in
Google Scholar
PubMed
Search for other papers by Seung Myung Dong in
Google Scholar
PubMed
Search for other papers by Jae-Goo Kang in
Google Scholar
PubMed
Search for other papers by Jin Soo Lee in
Google Scholar
PubMed
Search for other papers by Junsun Ryu in
Google Scholar
PubMed
). Papillary thyroid carcinoma (PTC) comprises ∼90% of all thyroid malignancies and has an excellent prognosis with conventional therapies such as surgery and radioactive iodine therapy. Despite advances in the understanding of the underlying biological
Department of Pathology & Molecular Medicine, Queen’s University, Kingston, Ontario, Canada
Search for other papers by Eric Y Lian in
Google Scholar
PubMed
Department of Pathology & Molecular Medicine, Queen’s University, Kingston, Ontario, Canada
Search for other papers by Sarah M Maritan in
Google Scholar
PubMed
Department of Pathology & Molecular Medicine, Queen’s University, Kingston, Ontario, Canada
Search for other papers by Jessica G Cockburn in
Google Scholar
PubMed
Search for other papers by Katayoon Kasaian in
Google Scholar
PubMed
Department of Pathology & Molecular Medicine, Queen’s University, Kingston, Ontario, Canada
Search for other papers by Mathieu J F Crupi in
Google Scholar
PubMed
Search for other papers by David Hurlbut in
Google Scholar
PubMed
Department of Medical Genetics, University of British Columbia, British Columbia Cancer Research Centre, Vancouver, British Columbia, Canada
Search for other papers by Steven J M Jones in
Google Scholar
PubMed
Search for other papers by Sam M Wiseman in
Google Scholar
PubMed
Department of Pathology & Molecular Medicine, Queen’s University, Kingston, Ontario, Canada
Search for other papers by Lois M Mulligan in
Google Scholar
PubMed
in sporadic forms of MTC ( Mulligan 2014 ). In contrast, in the follicular cell tumour papillary thyroid carcinoma (PTC), rearrangements of the RET gene result in a constitutively active RET kinase fusion protein (RET/PTC) localised in the cytosol
Search for other papers by Seo Ki Kim in
Google Scholar
PubMed
Search for other papers by Jung-Woo Woo in
Google Scholar
PubMed
Search for other papers by Jun Ho Lee in
Google Scholar
PubMed
Search for other papers by Inhye Park in
Google Scholar
PubMed
Search for other papers by Jun-Ho Choe in
Google Scholar
PubMed
Search for other papers by Jung-Han Kim in
Google Scholar
PubMed
Search for other papers by Jee Soo Kim in
Google Scholar
PubMed
Introduction With a rapidly increasing incidence worldwide, papillary thyroid carcinoma (PTC) represents the majority of thyroid cancer cases ( Ahn & Park 2009 , Siegel et al . 2014 ). The recently discovered BRAF V600E mutation (hereafter